USFDA Nod to Lupin to Market Tablets Used For Treatment of HIV Virus
This image is for representation purpose only.
Pharma major Lupin has received tentative approval for its Abacavir Sulfate and Lamivudine tablets from the USFDA to market generic version of ViiV Healthcare company's Epzicom tablets.
"Lupin's Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare company's Epzicom tablets, 600 mg/300 mg.
"Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection," a company statement said today.
The statement further said, "We have received tentative approval from USFDA for Abacavir Sulfate and Lamivudine tablets, to market a generic version of ViiV Healthcare company's Epzicom tablets."
Epzicom tablets had the US sales of USD 426 million.
The company is a significant player in cardiovascular, diabetology, asthma, paediatric and anti-infective space and holds global leadership position in the Anti-TB segment.
Recommended For You
- ICC Still Open to Negotiate, Offers BCCI USD 390 Million
- Honor 8 Pro First Look: The 6GB RAM Competitor to OnePlus 3t
- Kareena, Karisma, Malaika, Amrita Step Out In Style For Brunch, See Pics
- Facebook's Adit Vaidya, On How Groups Can Help 184 Million Monthly Active Indian Users
- Are You the Biggest Baahubali Fan Ever? Here's Your Chance to Prove It